Antibiotic resistance and the COVID‐19 pandemic: A dual crisis with complex challenges in LMICs

Abstract

AbstractBackground and AimsAntimicrobial resistance (AMR), a global health crisis of mounting urgency, has been further complicated by the ongoing COVID‐19 pandemic. The intricate relationship between these two phenomena is especially pronounced in low‐ and middle‐income countries (LMICs) due to the distinct obstacles encountered by their healthcare systems and policy structures. This study aims to explore the complex challenges arising from the coexistence of these two crises in LMICs and proffer specific recommendations for holistic management.MethodsAn exhaustive bibliographic survey was executed, employing search queries in specialized databases such as PubMed, SCOPUS, and Web of Science's SCI‐EXPANDED index. The timeframe for the literature search extended from January 2020 to January 2023. The search strategy employed key terms including antibiotic resistance, AMR, COVID‐19 pandemic, low‐ and middle‐income countries, SARS‐CoV‐2, and LMICs.ResultsThe pandemic has aggravated various drivers of AMR in LMICs, including limited capabilities, weak frameworks, and socioeconomic factors. New challenges have emerged, such as disruptions in the antibiotic supply chain and an increased risk of healthcare‐associated infections. The interaction between these drivers presents a complex problem that demands a coordinated response. Specific recommendations include strengthening health systems, funding research and innovation, and enhancing infection prevention control measures.ConclusionThe coexistence of AMR and the COVID‐19 pandemic in LMICs demands an integrated approach involving multiple stakeholders. Emphasis must be placed on constructing aligned regulatory frameworks, nurturing regional collaborations, and focusing on accessible therapeutic options. The study underscores the necessity for actionable strategies to achieve sustainable access to clean water and sanitation and also highlights the importance of long‐term planning, funding, and specialized expertise in emerging modalities like phage therapy.